Evidence map›Paper›PMID 34978891›Full record

ArticleAntimicrobial agents and chemotherapy2022

Is the Success of Cefazolin plus Ertapenem in Methicillin-Susceptible Staphylococcus aureus Bacteremia Based on Release of Interleukin-1 Beta?

Dan Smelter, Mary Hayney, George Sakoulas, Warren Rose

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Ertapenem Combined With Anti-The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Adjunctive β-lactams forTherapeutic advances in infectious disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Dan SmelterSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-9181-0786
Mary HayneySchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
George SakoulasDivision of Host-Microbe Systems & Therapeutics, Center for Immunity, Infection & Inflammation, University of California-San Diego School of Medicine, La Jolla, California, USA.
Warren RoseSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-5012-5993
University of Wisconsin–Madison · USUniversity of California San Diego · US

Funding

HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI32627
6 · The paper itself

Abstract

Cefazolin and ertapenem have been shown to be an effective salvage regimen for refractory methicillin-susceptible Staphylococcus aureus bacteremia. Our findings suggest cefazolin plus ertapenem

Indexed as

BacteremiaStaphylococcal InfectionsAnti-Bacterial AgentsCefazolinErtapenemHumansInterleukin-1betaMethicillinStaphylococcus aureusAnti-Bacterial AgentsCefazolinErtapenemInterleukin-1betaMethicillinantimicrobial combinationsbeta-lactamsimmunologyinnate immunityin vitro

Identifiers

PMID34978891
PMCPMC8846438
OpenAlexW4205688924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.